中国
化学
前药
医学物理学
中子俘获
医学
药理学
政治学
硼
有机化学
法学
作者
Xi-Yang Cui,Yu Liu,Changlun Wang,Zihao Wen,Yichen Li,Haocheng Tang,Juan Diwu,Yong Yang,Mengchao Cui,Zhibo Liu
出处
期刊:Radiochimica Acta
[Oldenbourg Wissenschaftsverlag]
日期:2022-04-21
卷期号:110 (6-9): 765-784
标识
DOI:10.1515/ract-2021-1137
摘要
Abstract This review provides an essential overview on the progress of rapidly-developing China’s radiopharmaceuticals in recent years (2014–2021). Our discussion reflects on efforts to develop potential, preclinical, and in-clinical radiopharmaceuticals including the following areas: (1) brain imaging agents, (2) cardiovascular imaging agents, (3) infection and inflammation imaging agents, (4) tumor radiopharmaceuticals, and (5) boron delivery agents (a class of radiopharmaceutical prodrug) for neutron capture therapy. Especially, the progress in basic research, including new radiolabeling methodology, is highlighted from a standpoint of radiopharmaceutical chemistry. Meanwhile, we briefly reflect on the recent major events related to radiopharmaceuticals along with the distribution of major R&D forces (universities, institutions, facilities, and companies), clinical study status, and national regulatory supports. We conclude with a brief commentary on remaining limitations and emerging opportunities for China’s radiopharmaceuticals.
科研通智能强力驱动
Strongly Powered by AbleSci AI